Is Phytoceramides Skin Hydration Randomized Trial safe?

Updated August 2026

Quick Answer

Phytoceramides Skin Hydration Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: This increase has significantly impacted the costs associated with medical treatment and resulted in additional expenses for patients and their families [].

Key Takeaways

  • 01This increase has significantly impacted the costs associated with medical treatment and resulted in additional expenses for patients and their families []. [Ali Sibel (2024)]
  • 027 8 10 11 Genetic factors contribute to the complexity of the pathophysiology of AD, as certain polymorphisms are associated with changes in skin barrier function and immune responses. [Ali Sibel (2024)]
  • 03For instance, mutations in the filaggrin gene have been linked to a higher risk of developing AD [,]. [Ali Sibel (2024)]
  • 041 1 2 3 4 4 1 Atopic dermatitis (AD) is a chronic inflammatory skin disease that mainly affects children, with a prevalence of 10 to 20% []. [Ali Sibel (2024)]
The current Migaku evidence database contains 2 reusable source documents for Phytoceramides Skin Hydration Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - This increase has significantly impacted the costs associated with medical treatment and resulted in additional expenses for patients and their families []. [Ali Sibel (2024); evidence level 3] - 7 8 10 11 Genetic factors contribute to the complexity of the pathophysiology of AD, as certain polymorphisms are associated with changes in skin barrier function and immune responses. [Ali Sibel (2024); evidence level 3] - For instance, mutations in the filaggrin gene have been linked to a higher risk of developing AD [,]. [Ali Sibel (2024); evidence level 3] - 1 1 2 3 4 4 1 Atopic dermatitis (AD) is a chronic inflammatory skin disease that mainly affects children, with a prevalence of 10 to 20% []. [Ali Sibel (2024); evidence level 3] - AD is characterized by elevated levels of skin eosinophils, neutrophils, and mast cells; lymphocyte infiltration; and increased immunoglobulin (Ig) E levels []. [Pareek Ashutosh (2024); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Emerging Treatments and New Vehicle Formulations for Atopic Dermatitis
  2. Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives